Table of Contents Author Guidelines Submit a Manuscript
Journal of Pharmaceutics
Volume 2013 (2013), Article ID 390425, 5 pages
http://dx.doi.org/10.1155/2013/390425
Research Article

Buckysomes: New Nanocarriers for Anticancer Drugs

1Division of Cardiology, Department of Internal Medicine, The University of Texas Health Science Center at Houston, 1881 East Road, Houston, TX 77054, USA
2Biomatrica, 5627 Oberlin Drive, San Diego, CA 92121, USA
3Graduate Schools of Biomedical Sciences, The University of Texas Health Science Center at Houston, 6767 Bertner Ave, Houston, TX 77030, USA
4Department of Anesthesiology, The University of Texas Health Science Center at Houston, 6431 Fannin Street, Houston, TX 7703, USA
5Casscells & Associates, LLC, 7111 Davis Court, McLean, VA 22101, USA

Received 28 November 2012; Accepted 1 February 2013

Academic Editor: Awesh Yadav

Copyright © 2013 Delia Danila et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Buckysomes, liposome-like vesicles comprised of dendritic C60 subunits that self-assemble into unilamellar vesicles, are unique nanovectors that have utility in drug delivery. We have prepared paclitaxel-embedded buckysomes (PEBs) and examined biodistriubition profiles with commercially available formulations of the drug. As compared to Abraxane, an albumin-bound formulation of paclitaxel, PEBs showed higher tissue accumulation in the liver and the kidney at 45 and 60 minutes and in the lungs at 30 minutes, making them suitable drug-delivery carriers for short-term therapy to the mentioned organs. These buckysomes can be further functionalized to specifically deliver paclitaxel to the tumor site.
{"cc_re__cc_re__cc_by_3_0": ["t of Anesthesiology, The University of Texas Health Science Center at Houston, 6431 Fannin Street, Houston, TX 7703, USA<br /><sup>5</sup>Casscells &#x26; Associates, LLC, 7111 Davis Court, McLean, VA 22101, USA<br /></p>\r\n           \r\n      \r\n\r\n\r\n\r\n\r\n<p>Received 28 November 2012; Accepted 1 February 2013</p>                \r\n<p>Academic Editor: Awesh Yadav</p>    <div class=\"xml-content\">\r\n        <p>Copyright &#xa9; 2013 Delia Danila et al. This is an open access article distributed under the <a rel=\"license\" href=\"http://creativecommons.org/licenses/by/3.0/\">  Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.\r\n        </p>\r\n    </div>\r\n<div id=\"divXMLContent\" class=\"xml-content\">\r\n<h4>Abstract</h4><p>Buckysomes, liposome-like vesicles comprised of dendritic C60 subunits that self-assemble into unilamellar vesicles, are unique nanovectors that have utility in drug delivery. We have prepared paclitaxel-embedded buckysomes (PEBs) and exam"], "copyright__copyright__copyright": ["mbedded buckysomes (PEBs) and examined biodistriubition profiles with commercially available formulations of the drug. As compared to Abraxane, an albumin-bound formulation of paclitaxel, PEBs showed higher tissue accumulation in the liver and the kidney at 45 and 60 minutes and in the lungs at 30 minutes, making them suitable drug-delivery carriers for short-term therapy to the mentioned organs. These buckysomes can be further functionalized to specifically deliver paclitaxel to the tumor site."]}